WEZLANA (ustekinumab-auub) by Amgen is interleukin-12 antagonists [moa]. Approved for interleukin-12 antagonist [epc]. First approved in 2023.
Drug data last refreshed 12h ago · AI intelligence enriched 2mo ago
WEZLANA (ustekinumab-auub) is an Amgen-developed monoclonal antibody biosimilar to Stelara that antagonizes interleukin-12 to treat immune-mediated inflammatory diseases. It is administered via intravenous or subcutaneous injection and represents a follow-on biologic to the reference product. The drug targets patients with conditions driven by IL-12 signaling pathways.
Early-stage growth trajectory with moderate competitive pressure (30%) suggests expanding commercial teams focused on market penetration and payer access strategies.
Interleukin-12 Antagonists
Interleukin-12 Antagonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on WEZLANA at Amgen? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on WEZLANA positions you in the high-stakes biosimilar competitive landscape, where success depends on payer negotiations, health economics, and rapid market penetration rather than novel science. Expect dynamic commercial organization building and significant focus on reimbursement strategy as the product scales.